Designation of imidazole-containing dipeptides as pharmacological chaperones

Human and Experimental Toxicology

Volumn 30, Issue 7, 2011, Pages 736-761

  Babizhayev, Mark A ^a,b  

^a Innovative Vision Products Inc   (Russian Federation)

^b MOSCOW HELMHOLTZ RESEARCH INSTITUTE OF EYE DISEASES   (Russian Federation)

Author keywords

age related cataract; cosmetic science; human cataractous lenses; macular degeneration; ophthalmic treatment; skin care

Indexed keywords

ALPHA CRYSTALLIN; ANTIOXIDANT; ASCORBIC ACID; BETA CRYSTALLIN; CALNEXIN; CALRETICULIN; CARCININE; CARNOSINE; CHAPERONE; DIPEPTIDE; EYE DROPS; FERROUS ION; GAMMA CRYSTALLIN; HEAT SHOCK PROTEIN 100; HEAT SHOCK PROTEIN 25; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMIDAZOLE; LIPID HYDROPEROXIDE; LIPID PEROXIDASE; LIPOSOME; N ACETYLCARNOSINE; PEPTIDOMIMETIC AGENT; PROTEASOME; PROTEIN; UNCLASSIFIED DRUG;

AGE RELATED CATARACT; AGING; ANTIOXIDANT ACTIVITY; CATARACT; DRUG DELIVERY SYSTEM; EYE DISEASE; GLAUCOMA; HUMAN; IONTOPHORESIS; LENS; LIPID PEROXIDATION; OCULAR COMPLICATION OF DIABETES; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SKIN CARE; SKIN CELL; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

CARNOSINE; CATARACT; DRUG CARRIERS; HUMANS; IMIDAZOLES; LIPID PEROXIDATION; MACULAR DEGENERATION; MOLECULAR CHAPERONES; OXIDATIVE STRESS;

EID: 79959700956     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327110377526     Document Type: Review

References (95)

1. Hartl FU Molecular chaperones in cellular protein folding. Nature 1996 ; 381: 571-579.
2. Gething MJ, Sambrook J. Protein folding in the cell. Nature 1992 ; 355: 33-45.
3. Fenton WA, Horwich AL GroEL-mediated protein folding. Protein Sci 1997 ; 6: 743-760. (Pubitemid 27154801)
4. Zhang C., Kim SH Overview of structural genomics: from structure to function. Curr Opin Chem Biol 2003 ; 7: 28-32. (Pubitemid 36126489)
5. Babizhayev MA Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. Life Sci 2006 ; 78: 2343-2357.
6. Severin SE Problems concerned with the biological activity of naturally occurring imidazole compounds. Proceedings of Plen Sess. Seventh International Biochemical Congress, 1964, NY, p. 45-61.
7. Boldyrev AA, Severin SE The histidine-containing dipeptides, carnosine and anserine: distribution, properties and biological significance. Adv Enzyme Regul 1990 ; 30: 175-194.
8. Yan H., Harding JJ Carnosine protects against the inactivation of esterase induced by glycation and a steroid. Biochim Biophys Acta 2005 ; 1741: 120-126. (Pubitemid 40824997)
9. Babizhayev MA, Guiotto A., and Kasus-Jacobi A. N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. J Drug Target 2009 ; 17: 36-63.
10. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kurysheva NI, et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001 ; 22: 979-994. (Pubitemid 32522975)
11. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D 2002 ; 3: 87-103. (Pubitemid 37062609)
12. Babizhayev MA, Deyev AI, Yermakova VN, Remenschikov VV, and Bours J. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther 2006 ; 1: 91-116.
13. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, and Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D 2004 ; 5: 125-139. (Pubitemid 38780076)
14. Babizhayev MA, 2004. Method for topical treatment of eye disease and composition and device for said treatment. PCT Patent Application. International Publication Number WO 2004 / 028536A1, International Publication 8 April 2004.
15. Babizhayev MA Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J Pharmacol Toxicol 2006 ; 1: 201-233.
16. Babizhayev MA Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuvenation Res 2004 ; 7: 186-198.
17. Babizhayev MA, Yermakova VN, Deyev AI, and Seguin MC Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti Aging Med 2000 ; 3: 43-62.
18. Trouba KJ, Hamadeh HK, Amin RP, and Germolec DR Oxidative stress and its role in skin disease. Antioxid Redox Signal. 2002 ; 4: 665-673. (Pubitemid 35001451)
19. Santosa S., Jones PJ Oxidative stress in ocular disease: does lutein play a protective role? CMAJ 2005 ; 173: 861-862. (Pubitemid 41504996)
20. Bai C., Biwersi J., Verkman AS, and Matthay MA A mouse model to test the in vivo efficacy of chemical chaperones. J Pharmacol Toxicol Methods 1998 ; 40: 39-45. (Pubitemid 29062905)
21. Perlmutter DH Chemical chaperones: a pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 2002 ; 52: 832-836. (Pubitemid 35379461)
22. Welch WJ, Brown CR Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1996 ; 1: 109-115. (Pubitemid 126670772)
23. Diamant S., Eliahu N., Rosenthal D., and Goloubinoff P. Chemical chaperones regulate molecular chaperones in vitro and in cells under combined salt and heat stresses. J Biol Chem 2001 ; 276: 39586-39591.
24. Babizhayev MA, Seguin MC, Gueyne J., Evstigneeva RP, Ageyeva EA, and Zheltukhina GA L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanyl-histamine) act as natural antioxidants with hydroxyl-radical- scavenging and lipid-peroxidase activities. Biochem J 1994 ; 304: 509-516. (Pubitemid 24368231)
25. Arnould JM, Frentz R. Carcinine (β-alanyl-histamine): rapid synthesis and action on vertebrate blood pressure. Arch Int Physiol Biochim 1977 ; 85: 339-350. (Pubitemid 8119216)
26. Pegova A., Abe H., and Boldyrev A. Hydrolysis of carnosine and related compounds by mammalian carnosinases. Comp Biochem Physiol B Biochem Mol Biol 2000 ; 127: 443-446.
27. Babizhayev MA Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta 1989 ; 1004: 363-371.
28. Babizhayev MA, Costa EB Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochim Biophys Acta 1994 ; 1225: 326-337. (Pubitemid 24066585)
29. Babizhayev MA Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev Ind Pharm 2008 ; 34: 1071-1089.
30. Miyachi Y., Imamura S., and Niwa Y. Decreased skin superoxide dismutase activity by a single exposure of ultraviolet radiation is reduced by liposomal superoxide dismutase pretreatment. J Investigat Dermatol 1987 ; 89: 111-112. (Pubitemid 17084195)
31. Bloemendal H., deJong W., Jaenicke R., Lubsen NC, Slingsby C., and Tardieu A. Ageing and vision: structure, stability and function of lens crystallins. Prog Biophys Mol Biol 2004 ; 86: 407-485. (Pubitemid 39081525)
32. Horwitz J. Alpha crystallin can function as a molecular chaperone. Proc Natl Acad Sci USA 1992 ; 89: 10449-10453.
33. Spector A. The search for a solution to senile cataracts. Procter lecture. Invest Ophthalmol Vis Sci 1984 ; 25: 130-145.
34. Nagaraj RH, Sell DR, Prabhakaram M., Ortwerth BJ, and Monnier VM High correlation between pentosidine protein crosslinks and pigmentation implicates ascorbate oxidation in human lens senescence and cataractogenesis. Proc Natl Acad Sci USA 1991 ; 88: 10257-10261. (Pubitemid 21915814)
35. Andley UP, Clark BA Generation of oxidants in the near-UV photooxidation of human lens alpha-crystallin. Invest Ophthalmol Vis Sci 1989 ; 30: 706-713. (Pubitemid 19117192)
36. McDermott M., Chiesa R., Roberts JE, and Dillon J. Photooxidation of specific residues in alpha-crystallin polypeptides. Biochemistry 1991 ; 30: 8653-8660.
37. Takemoto L., Boyle D. Increased deamidation of asparagine during human senile cataractogenesis. Mol Vis 2000 ; 6: 164-168.
38. Lorand L. Transglutaminase mediated cross-linking of proteins and cell aging: the erythrocyte and lens models. In: Zappia V (ed.) Advances in post-translational modifications of proteins and aging. New York: Plenum Press, 1988, p. 79-94.
39. Srivastava K., Chaves JM, Srivastava OP, and Kirk M. Multi-crystallin complexes exist in the water-soluble high molecular weight protein fractions of aging normal and cataractous human lenses. Exp Eye Res 2008 ; 87: 356-366.
40. Babizhayev MA, Kasus-Jacobi A. Imidazole-containing peptide-based compounds in sight-threatening age-related eye diseases. Expert Rev Ophthalmol 2009 ; 4: 581-586.
41. Attanasio F., Cataldo S., Fisichella S., Nicoletti S., Nicoletti VG, Pignataro B., et al. Protective effects of L- and D-carnosine on alpha-crystallin amyloid fibril formation: implications for cataract disease. Biochemistry 2009 ; 48: 6522-6531.
42. Bonnefont-Rousselot D., Bastard JP, Jaudon MC, and Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab. 2000 ; 26: 163-176. (Pubitemid 30435761)
43. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996 ; 28: 419-426. (Pubitemid 26380001)
44. Baynes JW The role of AGEs in aging: causation or correlation. Exp Gerontol 2001 ; 36: 1527-1537. (Pubitemid 32771329)
45. Lohwasser C., Neureiter D., Weigle B., Kirchner T., and Schuppan D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol 2006 ; 126: 291-299. (Pubitemid 43323163)
46. Stitt AW, Curtis TM Advanced glycation and retinal pathology during diabetes. Pharmacol Rep 2005 ; 57: 156-168.
47. Stitt AW, McGoldrick C., Rice-McCaldin A., McCance DR, Glenn JV, Hsu DK, et al. Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 2005 ; 54: 785-794. (Pubitemid 40322083)
48. Hunt JV, Bottoms MA, and Mitchinson MJ Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. Biochem J 1993 ; 291: 529-535. (Pubitemid 23127038)
49. Babizhayev MA, Micans P., Guiotto A., and Kasus-Jacobi A. N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. Am J Ther 2009 ; 16: 517-533.
50. Szwergold BS Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases. Biochem Biophys Res Commun 2005 ; 336: 36-41. (Pubitemid 41253399)
51. Babizhayev MA, Meguro K. 2004. Combined use of carnosinase inhibitor with L-carnosines and composition. WO 2004 /064866 PCT/JP2004/000351. Filed 20 January 2003.
52. Babizhayev MA, Seguin MC Coupling product obtained from histamine and an amino acid. US Patent Number 5, 792, 784. Date of Patent 11 August 1998.
53. Conner JR, Beisswenger PJ, and Szwergold BS Some clues as to the regulation, expression, function, and distribution of fructosamine-3-kinase and fructosamine-3-kinase-related protein. Ann N Y Acad Sci 2005 ; 1043: 824-836. (Pubitemid 41123977)
54. Guiotto A., Ruzza P., Babizhayev MA, and Calderan A. Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg Med Chem 2007 ; 15: 6158-6163. (Pubitemid 47088958)
55. Hipkiss AR Accumulation of altered proteins and ageing: causes and effects. Exp Gerontol 2006 ; 41: 464-473. (Pubitemid 43765899)
56. Schoneich C.. Protein modification in aging: an update. Exp Gerontol 2006 ; 41: 807-813.
57. Hipkiss AR Error-protein metabolism and ageing. Biogerontology 2009 ; 10: 523-529.
58. Babizhayev MA, Deev AI Free radical oxidation of lipids and thiol groups in the formation of a cataract. Biofizika 1986 ; 31: 109-114.
59. Boring CC, Squires TS, and Tong TT Cancer statistics, 1991. SA Cancer J Clin 1991 ; 41: 19-36.
60. Calabrese V., Randazzo SD, Morganti PG, and Rizza V. An ex vivo biochemical model to study the antioxidant clinical properties of cosmetic products in human antiaging skin care. Drugs Exp Clin Res 1999 ; 25: 43-49. (Pubitemid 29199592)
61. Spector A., Rothschild C. The effect of calcium upon the reaggregation of bovine alpha crystallin. Invest Ophthalmol 1973 ; 12: 225-231.
62. Biswas A., Das KP Zn2+ enhances the molecular chaperone function and stability of alpha-crystallin. Biochemistry 2008 ; 47: 804-816. (Pubitemid 351195452)
63. Ahmad MF, Singh D., Taiyab A., Ramakrishna T., Raman B., and Rao ChM. Selective Cu2+ binding, redox silencing, and cytoprotective effects of the small heat shock proteins alphaA- and alphaB-crystallin. J Mol Biol 2008 ; 382: 812-824.
64. Calabrese V., Scapagnini G., Catalano C., Bates TE, Geraci D., Pennisi G., et al. Regulation of heat shock protein synthesis in human skin fibroblasts in response to oxidative stress: role of vitamin E. Int J Tissue React. 2001 ; 23: 127-135. (Pubitemid 33121153)
65. Egbaria K., Ramachandran C., Kittayanond D., and Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies. Antimicrob Agents Chemother 1990 ; 34: 107-110. (Pubitemid 20019973)
66. Niemiec SM, Ramachandran C., and Weiner N. Influence of nonionic liposomal composition on topical delivery of peptide drugs into pilosebaceous units: an in vivo study using the hamster ear model. Pharm Res 1995 ; 12: 1184-1188.
67. Cevc G., Gebauer D., Stieber J., Schätzlein A., and Blume G. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta 1998 ; 1368: 201-215. (Pubitemid 28031874)
68. Barry BW Action of skin penetration enhancers-the Lipid Protein Partitioning theory. Int J Cosmet Sci. 1988 Dec; 10 (6). 281-93. (Pubitemid 19170030)
69. Foldvari M., Baca-Estrada ME, He Z., Hu J., Attah-Poku S., and King M. Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. Biotechnol Appl Biochem 1999 ; 30: 129-137.
70. Choi HK, Flynn GL, and Amidon GL Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on enkephalin metabolism and transport. Pharm Res 1990 ; 7: 1099-1106.
71. Lu MY, Lee D., and Rao GS Percutaneous absorption enhancement of leuprolide. Pharm Res 1992 ; 9: 1575-1579.
72. Green PG, Hinz RS, Kim A., Szoka FC Jr, and Guy RH Iontophoretic delivery of a series of tripeptides across the skin in vitro. Pharm Res 1991 ; 8: 1121-1127.
73. Heit MC, Monteiro-Riviere NA, Jayes FL, and Riviere JE Transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH): effect of repeated administration. Pharm Res 1994 ; 11: 1000-1003. (Pubitemid 24227646)
74. Tachibana K., Tachibana S. Transdermal delivery of insulin by ultrasonic vibration. J Pharm Pharmacol 1991 ; 43: 270-271.
75. Mitragotri S., Blankschtein D., and Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995 ; 269: 850-853.
76. Kang JH Protective effects of carnosine and N-acetylcarnosine on salsolinol-mediated Cu, Zn-superoxide dismutase inactivation. Bull Korean Chem Soc 2007 ; 208: 1881-1884.
77. Ukeda H., Hasegawa Y., Harada Y., and Sawamura M. Effect of carnosine and related compounds on the inactivation of human Cu,Zn- superoxide dismutase by modification of fructose and glycolaldehyde. Biosci Biotechnol Biochem 2002 ; 66: 36-43. (Pubitemid 39251085)
78. Kang JH, Kim KS, Choi SY, Kwon HY, Won MH, and Kang TC Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu,Zn-superoxide dismutase modification. Biochim Biophys Acta 2002 ; 1570: 89-96. (Pubitemid 34457805)
79. Babizhayev MA, Deyev AI Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim Biophys Acta 1989 ; 1004: 124-133. (Pubitemid 19178623)
80. Hobart LJ, Seibel I., Yeargans GS, and Seidler NW Anti-crosslinking properties of carnosine: significance of histidine. Life Sci 2004 ; 75: 1379-1389. (Pubitemid 38845036)
81. Mehta AD, Seidler NW Beta-alanine suppresses heat inactivation of lactate dehydrogenase. J Enzyme Inhib Med Chem 2005 ; 20: 199-203. (Pubitemid 40645510)
82. Yan H., Harding JJ Carnosine inhibits modifications and decreased molecular chaperone activity of lens alpha-crystallin induced by ribose and fructose 6-phosphate. Mol Vis 2006 ; 12: 205-214.
83. Seidler NW, Yeargans GS, and Morgan TG Carnosine disaggregates glycated alpha-crystallin: an in vitro study. Arch Biochem Biophys 2004 ; 427: 110-115. (Pubitemid 38725919)
84. Price DI, Rhett PM, Thorpe SR, and Baynes JW Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001 ; 276: 48967-48972.
85. Boldyrev AA, Dupin AM, Bunin AYa, Babizhayev MA, and Severin SE The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem Int 1987 ; 15: 1105-1113. (Pubitemid 18014870)
86. Hipkiss AR, Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun 1998 ; 248: 28-32. (Pubitemid 28418181)
87. Yamagishi SI, Nakamura K., and Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005 ; 1: 93-106.
88. Muranov KO, Dizhevskaia AK, Boldyrev AA, Karpova OE, Sheremet NL, Polunin GS, et al. [Search for chaperon-like anticataract drugs, the antiaggregants of lens crystallins. Communication. 1. Chaperon-like activity of N-acetyl carnosine dipeptide: in vitro study on a model of ultraviolet-induced aggregation of betaL-crystallin]. Vestn Oftalmol 2008 ; 124: 3-6.
89. Hipkiss AR, Brownson C., Bertani MF, Ruiz E., and Ferro A. Reaction of carnosine with aged proteins: another protective process? Ann N Y Acad Sci 2002 ; 959: 285-294. (Pubitemid 34457569)
90. Jonak C., Klosner G., and Trautinger F. Heat shock proteins in the skin. Int J Cosmet Sci 2006 ; 28: 233-241. (Pubitemid 44086776)
91. Calabrese V., Cornelius C., Mancuso C., Pennisi G., Calafato S., Bellia F., et al. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res 2008 ; 16. [Epub ahead of print].
92. Ohkawara T., Nishihira J., Nagashima R., Takeda H., and Asaka M. Polaprezinc protects human colon cells from oxidative injury induced by hydrogen peroxide: relevant to cytoprotective heat shock proteins. World J Gastroenterol 2006 ; 12: 6178-6181. (Pubitemid 44688168)
93. Mikami K., Otaka M., Watanabe D., Goto T., Endoh A., Miura K., et al. Zinc L-carnosine protects against mucosal injury in portal hypertensive gastropathy through induction of heat shock protein 72. J Gastroenterol Hepatol 2006 ; 21: 1669-1674. (Pubitemid 44410876)
94. Kosmaoglou M., Schwarz N., Bett JS, and Cheetham ME Molecular chaperones and photoreceptor function. Trends Mol Med 2001 ; 7: 414-421.
95. Gavin BA, Arruda SE, and Dolph PJ The role of carcinine in signaling at the Drosophila photoreceptor synapse. PLoS Genet 2007 ; 3: e206.